
binanceservices-ethusdt
Introduction to our strategy no description yet Quick Summary Metric Value Return % p.a. 19 Days active 410 …
tickers: NMRA
source: Benzinga
ticker | polarity | why? |
---|---|---|
NMRA | positively | The ticker (NMRA) could potentially be affected positively if the lawsuit successfully demonstrates that the company misled investors, as this could lead to a significant payout to shareholders, reinstating confidence in the company. This news can also act as a warning to the company in changing its practices and enhancing its transparency, which could improve shareholder trust. |
None so far…
NEW YORK, March 06, 2025 – The Gross Law Firm has issued a notice to shareholders of Neumora Therapeutics, Inc. (NMRA). The firm encourages shareholders who purchased shares during the specified class period to consider contacting them. The class period for this lawsuit begins on or about September 15, 2023. According to the complaint, defendants made materially false or misleading statements and failed to disclose certain information. The allegations include that Neumora amended the Phase Two trial inclusion criteria to include a broader patient population to justify its Phase Three Program. The company also added a prespecified analysis to the Phase Two statistical analysis plan. The complaint further alleges that the Phase Two Trials lacked adequate data to accurately predict the results of the KOASTAL-1 study. This is attributed to insufficient data on the patient population size and the ratio of male to female patients. The deadline for shareholders to register for this class action is April 7, 2025. Next Steps for Shareholders:
Introduction to our strategy no description yet Quick Summary Metric Value Return % p.a. 19 Days active 410 …
Introduction to our strategy no description yet Quick Summary Metric Value Return % p.a. -85 Days active 427 …
Introduction to our strategy no description yet Quick Summary Metric Value Return % p.a. -60 Days active 408 …